These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7925051)

  • 1. Efficacy and safety of inhaled Salmeterol (Serevent) as maintenance therapy for asthma in Nairobi.
    Odhiambo JA; Nganga LW; Gikonyo BM
    East Afr Med J; 1994 Feb; 71(2):88-92. PubMed ID: 7925051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
    Busse WW; Casale TB; Murray JJ; Petrocella V; Cox F; Rickard K
    Am J Manag Care; 1998 Nov; 4(11):1579-87. PubMed ID: 10338904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma.
    Martin RJ; Kraft M; Beaucher WN; Kiechel F; Sublett JL; LaVallee N; Shilstone J
    Ann Allergy Asthma Immunol; 1999 Aug; 83(2):121-6. PubMed ID: 10480584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma].
    Beeh KM; Beier J; Kornmann O; Wiewrodt R; Buhl R;
    Pneumologie; 2002 Feb; 56(2):91-7. PubMed ID: 11842346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
    Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
    Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open multi-centre study to assess the efficacy of inhaled salmeterol in bronchial asthma in Nigeria.
    Onadeko BO; Bamidele EO; Ekweani CN; Erabor GE
    Afr J Med Med Sci; 1994 Sep; 23(3):301-5. PubMed ID: 7604758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Dahl R; Chuchalin A; Gor D; Yoxall S; Sharma R
    Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of changing inhalation device from separate diskus of salmeterol and fluticasone propionate to combination diskus in asthma patients].
    Miyagawa T
    Arerugi; 2008 Nov; 57(11):1134-44. PubMed ID: 19052508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of salmeterol in patients with allergic bronchial asthma].
    Pacor ML; Biasi D; Cortina P; Maleknia T; Lunardi C
    Clin Ter; 1994 Aug; 145(8):131-4. PubMed ID: 7955958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
    Kerwin EM; Nathan RA; Meltzer EO; Ortega HG; Yancey SW; Schoaf L; Dorinsky PM
    Respir Med; 2008 Apr; 102(4):495-504. PubMed ID: 18206361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.
    Campbell LM; Anderson TJ; Parashchak MR; Burke CM; Watson SA; Turbitt ML
    Respir Med; 1999 Jul; 93(7):236-44. PubMed ID: 10464829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
    Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening A; Haahtela T; Holgate ST; Picado C; Leff JA
    Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids.
    You-Ning L; Humphries M; Du X; Wang L; Jiang J
    Int J Clin Pract; 2005 Jul; 59(7):754-9. PubMed ID: 15963199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salmeterol decreases eosinophilic cationic protein and rescue medication in patients inhaling beclomethasone dipropionate: preliminary study in mild and moderate asthma in Trinidad, West Indies.
    Pinto Pereira LM; Clement Y; Rouse J; Matthew J; Asgarali Z; Ramoutar D; Teelucksingh S
    Int J Clin Pharmacol Res; 2003; 23(2-3):69-74. PubMed ID: 15025036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate.
    Lundbäck B; Rönmark E; Lindberg A; Jonsson AC; Larsson LG; Pétavy F; James M
    Respir Med; 2006 Jan; 100(1):2-10. PubMed ID: 16243498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Better control of asthma symptoms with salmeterol].
    Kurzawa R; Barliński J
    Pol Merkur Lekarski; 1997 May; 2(11):336-9. PubMed ID: 9377685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
    Brogden RN; Faulds D
    Allergol Immunopathol (Madr); 1992; 20(2):72-84. PubMed ID: 1359777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of a controlled release formulation of salbutamol in the management of patients with asthma in Nairobi, Kenya.
    Gathua SN; Aluoch JA
    East Afr Med J; 1990 Dec; 67(12):850-5. PubMed ID: 2083519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.